Anti cancer agents capecitabine, sorafenib, sunitinib.
Conditions
Interventions
On three time points, at baseline, after 4- 6 weeks and at the end of treatment, fingerprints will be taken by one of the study coordinators by using a digital fingerprint scanner (present at outpatie
Sponsors
Erasmus Medical Center, Department of Medical Oncology
Department of Forensics
Police Force Hollands-Midden
Eligibility
Inclusion criteria
Inclusion criteria: • Patients using anti-cancer drugs (capecitabine, sunitinib, sorafenib) that are known for developing HFS or HFSR; • Age ≥ 18 years; • Written informed consent.
Exclusion criteria
Exclusion criteria: • Patients with symptomatic skin disease which affect hand palm and fingertips.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • To examine whether systemic anti-cancer drug-induced HSF or HFSR leads to changes in or loss of friction ridges. | — |
Secondary
| Measure | Time frame |
|---|---|
| • To compare the changes of friction ridges among patients. • To determine if the anti-cancer drug- induced HSF or HFSR leads to unidentifiable fingerprints for identification/individualization purposes using digital fingerprint scanners. • To determine whether the changes in friction ridges, caused by the anti- cancer drugs, are reversible when drug treatment is stopped. | — |
Contacts
Public ContactRon H.J. Mathijssen
Erasmus MC Rotterdam – Daniel den Hoed Cancer Center Department of Medical Oncology Room G4-80
Outcome results
None listed